StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine,
“Regeneration-Inducing Medicine™”.
| September 25, 2024 | Timely Disclosure Information | Notice Regarding Appointment of Director Candidates |
|---|---|---|
| September 25, 2024 | Timely Disclosure Information | StemRIM Announces Proposal for Approval of Issuance of Stock Options to our Company’s Executive Officers, Employees, and External Collaborators |
| September 13, 2024 | Financial Results Presentation Materials | Presentation Materials Financial Results for the the Fiscal Year Ended July 31, 2024 |
| September 11, 2024 | Timely Disclosure Information | Notice Regarding Differences between Non-consolidated Result s for Fiscal Year Ended July 31, 2024 and those for Previous Fiscal Year |
| September 11, 2024 | Financial Results | Non-consolidated Financial Results for the Fiscal Year Ended July 31, 2024 [Japanese GAAP] |
| April 25, 2023 | NEWS Release |
|---|
StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine, “Regeneration-Inducing Medicine™”.
“Regeneration-Inducing Medicine™” is an innovative new class of medicine that induces functional regeneration of tissues and organs in the patient's body by maximizing the human body's innate ability of tissue repairing.
We are pursuing research and development of new drugs based on a novel mechanism of action leading to recruitment of the patients’ own in-vivo stem cells to the damaged tissues for functional tissue regeneration without conventional cell-therapy approaches.
